Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592113 | SCV000705338 | uncertain significance | not provided | 2017-01-05 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001109648 | SCV001267009 | uncertain significance | Oculocutaneous albinism | 2017-04-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Labcorp Genetics |
RCV000592113 | SCV001693497 | pathogenic | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 222 of the TYR protein (p.Ile222Thr). This variant is present in population databases (rs34878847, gnomAD 0.3%). This missense change has been observed in individual(s) with oculocutaneous albinism (internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 499705). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt TYR protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV001591355 | SCV001821904 | likely benign | Tyrosinase-negative oculocutaneous albinism | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001821726 | SCV002070570 | uncertain significance | not specified | 2018-05-31 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001821726 | SCV005202470 | uncertain significance | not specified | 2024-07-30 | criteria provided, single submitter | clinical testing | Variant summary: TYR c.665T>C (p.Ile222Thr) results in a non-conservative amino acid change located in the Tyrosinase copper-binding domain (IPR002227) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00014 in 1612468 control chromosomes in the gnomAD database, including 1 homozygote. This frequency is not significantly higher than estimated for a pathogenic variant in TYR causing Oculocutaneous Albinism (0.00014 vs 0.0056), allowing no conclusion about variant significance. c.665T>C has been reported in the literature in at least one heterozygous individual affected with Oculocutaneous Albinism without detected second variant (e.g. Gao_2017). This report does not provide unequivocal conclusions about association of the variant with Oculocutaneous Albinism. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 28451379, 23504663). ClinVar contains an entry for this variant (Variation ID: 499705). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Fulgent Genetics, |
RCV005010575 | SCV005631342 | likely pathogenic | Tyrosinase-negative oculocutaneous albinism; Oculocutaneous albinism type 1B; SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN | 2024-04-08 | criteria provided, single submitter | clinical testing |